These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 32665011)

  • 1. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
    Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
    Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
    Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deubiquitination and Stabilization of PD-L1 by CSN5.
    Lim SO; Li CW; Xia W; Cha JH; Chan LC; Wu Y; Chang SS; Lin WC; Hsu JM; Hsu YH; Kim T; Chang WC; Hsu JL; Yamaguchi H; Ding Q; Wang Y; Yang Y; Chen CH; Sahin AA; Yu D; Hortobagyi GN; Hung MC
    Cancer Cell; 2016 Dec; 30(6):925-939. PubMed ID: 27866850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer.
    Huang J; Yin Q; Wang Y; Zhou X; Guo Y; Tang Y; Cheng R; Yu X; Zhang J; Huang C; Huang Z; Zhang J; Guo Z; Huo X; Sun Y; Li Y; Wang H; Yang J; Xue L
    Adv Sci (Weinh); 2024 Jun; 11(23):e2308045. PubMed ID: 38520088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.
    Li J; Li Y; Wang B; Ma Y; Chen P
    Biochem Biophys Res Commun; 2018 Jun; 500(2):132-138. PubMed ID: 29596838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
    Ma Y; Xia P; Wang Z; Xu J; Zhang L; Jiang Y
    Neoplasia; 2021 Sep; 23(9):912-928. PubMed ID: 34325342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1.
    Pan J; Qiao Y; Chen C; Zang H; Zhang X; Qi F; Chang C; Yang F; Sun M; Lin S; Tang Q; Li L; Wang M; Wu M; Liu Y; Lai C; Chen J; Chen G
    Cell Death Dis; 2021 Nov; 12(11):1051. PubMed ID: 34741014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity
    Liu Y; Liu X; Zhang N; Yin M; Dong J; Zeng Q; Mao G; Song D; Liu L; Deng H
    Acta Pharm Sin B; 2020 Dec; 10(12):2299-2312. PubMed ID: 33354502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.
    Huang X; Zhang Q; Lou Y; Wang J; Zhao X; Wang L; Zhang X; Li S; Zhao Y; Chen Q; Liang T; Bai X
    Cancer Immunol Res; 2019 Oct; 7(10):1580-1590. PubMed ID: 31399419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
    Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Link between Inflammation and Cancer.
    Grinberg-Bleyer Y; Ghosh S
    Cancer Cell; 2016 Dec; 30(6):829-830. PubMed ID: 27960080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
    Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
    J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
    Wang Z; Kang W; Li O; Qi F; Wang J; You Y; He P; Suo Z; Zheng Y; Liu HM
    Acta Pharm Sin B; 2021 Mar; 11(3):694-707. PubMed ID: 33777676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
    Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
    J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms.
    Guo J; Zhao J; Fu W; Xu Q; Huang D
    Front Immunol; 2022; 13():918314. PubMed ID: 35935969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer.
    Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W
    Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.